Search Within

Monica Nancy Fornier

Formats
  1. Journal Article (92)
  2. Meeting Abstract (63)
  3. Review (2)
  4. Editorial (1)
Groups
  1. Breast Medicine Service (158)
  2. Department of Medicine (158)
  3. Solid Tumor Oncology Division (158)
  4. Survivorship Research (158)
  5. Epidemiology and Biostatistics (64)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (58)

More Groups

People
  1. Clifford Hudis (72)
  2. Larry Norton (53)
  3. Chau Dang (38)
  4. Gabriella D'Andrea-Carlino (38)
  5. Andrew Seidman (37)
  6. Diana Lake (36)

More People

Years
  1. 2024 (3)
  2. 2023 (1)
  3. 2022 (1)
  4. 2021 (3)
  5. 2020 (6)
  6. 2019 (4)

More Years

Publications
  1. Journal of Clinical Oncology (34)
  2. Breast Cancer Research and Treatment (15)
  3. Annals of Oncology (11)
  4. Cancer Research (11)
  5. Clinical Breast Cancer (8)
  6. Clinical Cancer Research (7)

More Publications

Publishers
  1. American Society of Clinical Oncology (35)
  2. Springer (21)
  3. American Association for Cancer Research (19)
  4. Elsevier Inc. (17)
  5. Oxford University Press (13)
  6. Wiley Blackwell (10)

More Publishers

Results (158)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Eribulin mesylate in patients with locally advanced unresectable or metastatic breast cancer: Results and implications of the clinical trials
    Journal Article

    Ramnaraign, B.; Page, D.; Fornier, M.
    Breast Cancer Management (2015)

    Fulltext@MSK | Save
  • Denosumab and fracture risk in women with breast cancer
    Journal Article

    Farooki, A.; Fornier, M.
    Lancet (2015)

    Fulltext@MSK | Save
  • Phase I study of LJM716, BYL719, and trastuzumab in patients (pts) with HER2-amplified (HER2+) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Chandarlapaty, S.; Dickler, M. N.; Ulaner, G.; Zamora, S. J.; Sterlin, V.; Iasonos, A.; Coughlin, C. M.; Morozov, A.; Ero, J.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • A combined screening approach of Fracture (Fx) Risk Algorithm (FRAX) and Trabecular Bone Score (TBS) to identify osteoporotic-range fracture risk (ORFR) in breast cancer (BC) patients treated with adjuvant aromatase inhibitor (AI)
    Meeting Abstract

    Page, D. B.; Mariotti, V.; Davydov, O.; Patil, S.; Hans, D.; Hudis, C. A.; Farooki, A.; Fornier, M. N.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Atypical femur fractures associated with use of bisphosphonates and denosumab
    Journal Article

    Farooki, A.; Fornier, M.; Boland, P.
    Annals of Oncology (2015)

    Fulltext@MSK | Save
  • Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer
    Journal Article

    Dang, C.; Iyengar, N.; Datko, F.; D'Andrea, G.; Theodoulou, M.; Dickler, M.; Goldfarb, S.; Lake, D.; Fasano, J.; Fornier, M.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Serum metabolomic profiles evaluated after surgery may identify patients with oestrogen receptor negative early breast cancer at increased risk of disease recurrence. Results from a retrospective study
    Journal Article

    Tenori, L.; Oakman, C.; Morris, P. G.; Gralka, E.; Turner, N.; Cappadona, S.; Fornier, M.; Hudis, C.; Norton, L.; Luchinat, C.; more...
    Molecular Oncology (2015)

    Fulltext@MSK | Save
  • Utilizing microtubule dynamics inhibitor therapeutics in the management of patients with metastatic breast cancer
    Journal Article

    Seidman, A. D.; Brufsky, A.; Fornier, M. N.
    Clinical Breast Cancer (2014)

    Fulltext@MSK | Save
  • Phase II feasibility study of paclitaxel (T) with trastuzumab (H) and lapatinib (L) for node-negative, HER2-positive breast cancer (BC)
    Meeting Abstract

    Iyengar, N. M.; Fornier, M. N.; Sugarman, S.; Theodoulou, M.; Troso-Sandoval, T. A.; D'Andrea, G.; Drullinsky, P.; Fasano, J.; Gajria, D.; Goldfarb, S. B.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with HER2-overexpressing metastatic breast cancer (MBC)
    Meeting Abstract

    Datko, F. M.; D'Andrea, G.; Dickler, M. N.; Goldfarb, S. B.; Theodoulou, M.; Lake, D.; Fornier, M. N.; Modi, S.; Fasano, J.; Comen, E. A.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save